NVS Phase 3 readout: a positive outcome, -1.0%

On February 28, 2026, JDQ443 — Novartis AG (Non-Small Cell Lung Cancer) reached its Phase 3 readout. The result was a positive outcome, and the stock moved -1.0% in the window around the event. It had already run +15.6% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.